Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX)
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
Allograft vascular thrombosis is a devastating complication in kidney transplantation in adults and older children. Though uncommon, it is often irreversible and represents the main cause of graft loss within after kidney transplantation in adults and in the first post-operative year in children. Since allograft thrombosis is usually observed in the first 48h post-operatively, the need to promptly achieve appropriate anticoagulation in at-risk patients is of utmost importance. However, no consensus exists regarding the optimal prophylaxis in the peri-transplant period and the following dose-adjustment, and practices are highly heterogeneous among centers. Moreover, the therapeutic target is very narrow and antithrombotic agents may conversely increase the risk of allograft hematoma. Enoxaparin is a low molecular weight heparin commonly used in this context, but off-label in children. Therapeutic ranges are based on anti-Xa levels 4 to 6 hours following injection and extrapolated from adults although evidences suggest that such extrapolation may be inappropriate in many circumstances. The current pediatric practice of dose adjustment to achieve and maintain a target anti-Xa range is empirical and dependent on the physician. The aim of the proposed clinical trial is to assess the efficacy/safety profile of this bayesian-based dose optimization in the clinical setting, as compared to the current practices of empirical adjustment. This should greatly improve the personalized management of renal transplanted children, a subset of patients with singular renal function and little-investigated pharmacokinetics and help standardizing and rationalizing practices.
Official title: Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients
Key Details
Gender
All
Age Range
2 Years - 20 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2023-06-28
Completion Date
2026-02-26
Last Updated
2026-07-07
Healthy Volunteers
No
Conditions
Interventions
Bayesian based dose adjustment of enoxaparin
A first recommended dose of enoxaparin 50 IU/kg subcutaneously is administered during transplantation or within the first 24 hours. Then a Bayesian estimate of individual pharmacokinetics is performed to adapt the next twice daily (Hour 12;Hour 24) enoxaparin dose until achievement of the target on two consecutive measurements. Then anti-Xa activity will be evaluated once a day until day 7.
Usual dose adjustment of enoxaparin
A first recommended dose of enoxaparin 50 IU/kg is administered during transplantation or within the first 24 hours. Then anti-Xa activity is measured and twice-daily (hour 12 ; hour 24) enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers to target.
Locations (10)
Hôpital Pellegrin
Bordeaux, France
CHU Félix Guyon
La Réunion, France
Hôpital Mère Enfant
Lyon, France
Hôpital de la Villeneuve
Montpellier, France
Hôtel Dieu
Nantes, France
Hôpital Necker Enfants Malades
Paris, France
Hôpital Robert Debré
Paris, France
Hôpital de Hautepierre
Strasbourg, France
Hôpital des Enfants
Toulouse, France
Hôpital Necker - Enfants malades
Paris, Île-de-France Region, France